RTTNews | Dec 31, 2020 08:23AM EST

08:23 Thursday, December 31, 2020 (RTTNews.com) - Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, said Thursday it has signed a production agreement with Tergus Pharma for both GLP and GMP materials associated with its novel cancer treatment drug, HT-001.

The production agreement comes as Hoth has requested a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration or FDA to discuss a proposed drug development program for the novel treatment.

HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are used for treatment of cancers.

HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy.

"Hoth management is pleased with the advancement of our HT-001 treatment throughout the developmental process. Patients struggling with dermatological ailments have been known to halt, and even discontinue potentially life-saving oncology treatments," said Robb Knie, CEO of Hoth Therapeutics.

Read the original article on RTTNews ( https://www.rttnews.com/3156977/hoth-therapeutics-inks-production-deal-with-tergus-pharma-for-ht-001-glp-and-gmp-materials.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved